# This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.

> **NCT05486975** · EARLY_PHASE1 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** CT0591CP Cells

## Key facts

- **NCT ID:** NCT05486975
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-10
- **Primary completion:** 2025-01-29
- **Final completion:** 2025-01-29
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05486975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05486975, "This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05486975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*